24.1.2018 General


10 thoughts on “24.1.2018 General”

  1. Neoadjuvant oncolytic virotherapy before surgery sensitizes triple-negative breast cancer to immune checkpoint therapy
    Marie-Claude Bourgeois-Daigneault1,2,*, Dominic Guy Roy1,2,†, Amelia Sadie Aitken1,2,†, Nader El Sayes1,2,†, Nikolas Tim Martin1,2, Oliver Varette1,2, Theresa Falls1, Lauren Elizabeth St-Germain1, Adrian Pelin1,2, Brian Dennis Lichty3, David Francis Stojdl2,4, Guy Ungerechts1, Jean-Simon Diallo1,2 and John Cameron Bell1,2,*



  2. Cell. 2018 Jan 11;172(1-2):373-386.e10. doi: 10.1016/j.cell.2017.11.010. Epub 2017 Dec 7.
    A Living Biobank of Breast Cancer Organoids Captures Disease Heterogeneity.
    Sachs N1, de Ligt J2, Kopper O3, Gogola E4, Bounova G5, Weeber F6, Balgobind AV7, Wind K8, Gracanin A8, Begthel H8, Korving J8, van Boxtel R2, Duarte AA4, Lelieveld D9, van Hoeck A2, Ernst RF2, Blokzijl F2, Nijman IJ2, Hoogstraat M10, van de Ven M11, Egan DA9, Zinzalla V12, Moll J12, Boj SF13, Voest EE6, Wessels L14, van Diest PJ15, Rottenberg S16, Vries RGJ13, Cuppen E2, Clevers H17.
    Author information

    Breast cancer (BC) comprises multiple distinct subtypes that differ genetically, pathologically, and clinically. Here, we describe a robust protocol for long-term culturing of human mammary epithelial organoids. Using this protocol, >100 primary and metastatic BC organoid lines were generated, broadly recapitulating the diversity of the disease. BC organoid morphologies typically matched the histopathology, hormone receptor status, and HER2 status of the original tumor. DNA copy number variations as well as sequence changes were consistent within tumor-organoid pairs and largely retained even after extended passaging. BC organoids furthermore populated all major gene-expression-based classification groups and allowed in vitro drug screens that were consistent with in vivo xeno-transplantations and patient response. This study describes a representative collection of well-characterized BC organoids available for cancer research and drug development, as well as a strategy to assess in vitro drug response in a personalized fashion.



  3. Targeting RAS driven human cancer cells with antibodies to upregulated and essential cell-surface proteins

    Alexander John Martinko Charles Truillet Olivier Julien Juan Diaz Max A Horlbeck Gordon Whiteley Josip Blonder Jonathan S Weissman Sourav Bandyopadhyay Michael Evans James A Wells Is a corresponding author expand author listsee allhttps://elifesciences.org/articles/31098


Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s